Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist
Hellberg MR, McLaughlin MA, Sharif NA. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv Ophthalmol 2002; 47: S13-33.
Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes
Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmol 1993; 100: 1297-304.
Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost
Stewart WC, Kolker AE, Stewart JA. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol 2003; 135: 314-20.
Cystoid macular edema in a low-risk patient after switching from latanoprost to bimatoprost
Carrillo MM, Nicolela MT. Cystoid macular edema in a low-risk patient after switching from latanoprost to bimatoprost. Am J Ophthalmol 2004; 137: 966-8.
Choroidal detachement following extracapsular cataract extraction in a patient treated with latanoprost
Gupta R, Vernon SA. Choroidal detachement following extracapsular cataract extraction in a patient treated with latanoprost. Br J Ophthalmol 2001; 85: 1260.